Intra-Cellular Therapies (ITCI) : 7 investment research analysts covering Intra-Cellular Therapies (ITCI) have an average price target of $76.57 for the near short term. The highest target price given by the Brokerage Firm to the stock is $95 and the lowest target is $57 for the short term. Analysts expect the variance to be within $15.04 of the average price.
Intra-Cellular Therapies (ITCI) : Zacks Investment Research ranks Intra-Cellular Therapies (ITCI) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 5 research analysts is 1, which indicates as a Strong Buy.
Also, Piper Jaffray initiates coverage on Intra-Cellular Therapies (NASDAQ:ITCI). The rating major has initiated the coverage with overweight rating on the shares. The Analysts at Piper Jaffray announces a current price target of $57 per share. The rating by the firm was issued on June 2, 2016.
Intra-Cellular Therapies (NASDAQ:ITCI): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $40.35 and $40.02 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $40.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $40.63, notching a gain of 0.72% for the day. The total traded volume was 327,019 . The stock had closed at $40.34 on the previous day.
ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.